Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer

• DOI: 10.4143/crt.2013.45.4.325
• Publication Date: 2014-01-14T13:41:16Z
• Authors: Ji-Won Kim; Youngil Koh; Dong-Wan Kim; Yong-Oon Ahn; Tae Min Kim; Sae-Won Han; Do-Youn Oh; Se-Hoon Lee; Seock-Ah Im; Tae-You Kim; Dae Seog Heo; Yung-Jue Bang
• Keywords: Leukocytosis; Thrombocytosis; Univariate analysis

Purpose Vascular endothelial growth factor (VEGF)-A, VEGF165b, interleukin (IL)-1β, and transforming (TGF)-β1 are known to influence tumor angiogenesis. Clinical implications of these cytokines need be elucidated. Materials Methods Using clinical data baseline serum samples 140 consecutive patients with advanced non-small cell lung cancer who received platinum-based combination chemotherapy, we investigated the association among cytokine levels, treatment outcomes, as well leukocyte platelet counts. Results The median age was 64 years (range, 26 86 years). male female ratio 104:36. High TGF-β1 IL-1β levels were associated shorter progression-free survival, high VEGF-A overall survival in univariate analysis. VEGF165b not related outcomes. Leukocytosis thrombocytosis survival. multivariate analysis demonstrated that VEGF-A, IL-1β, leukocytosis significant prognostic factors (p=0.0497, p=0.047, p<0.001, respectively). recent pneumonia (p=0.937) correlated (p<0.001) (p=0.020) levels. Conclusion Serum TGF-1β, addition counts, shown Leukocyte counts Key words: factor, Interleukin-1beta, Transforming beta1, Leukocytes, Blood platelets, Non-small carcinoma